Menlo Reports First Quarter 2020 Financial Results and Provides Business Update
11 mai 2020 07h00 HE
|
Menlo Therapeutics Inc.
Conference Call Today at 8:30am Eastern Time BRIDGEWATER, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”),...
Menlo Therapeutics to Report First Quarter 2020 Financial Results on May 11
05 mai 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater China
23 avr. 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis
06 avr. 2020 07h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...
Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues
02 avr. 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...
Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer
24 mars 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...
Menlo Therapeutics Provides a Business Update in the Context of COVID-19
20 mars 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019
12 mars 2020 07h00 HE
|
Menlo Therapeutics Inc.
Foamix Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020 Menlo Conference Call and Webcast Scheduled for Thursday, March 12 at 8:30am Eastern Time ...
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
09 mars 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd....
Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
03 mars 2020 16h05 HE
|
Menlo Therapeutics Inc.
REDWOOD CITY, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of...